GlaxoSmithKline PLC Directorate Change (7553L)
July 21 2017 - 5:00AM
UK Regulatory
TIDMGSK
RNS Number : 7553L
GlaxoSmithKline PLC
21 July 2017
GlaxoSmithKline plc (the "Company")
Board and Committee changes
GSK today announces that Dr Laurie Glimcher has been appointed
to the Board of the Company as a Non-Executive Director and has
been deemed a Scientific and Medical Expert. Dr Glimcher will join
the Board on 1 September 2017.
Philip Hampton, Chairman of GlaxoSmithKline plc, said: "I am
delighted Laurie is joining the Board. Laurie brings a wealth of
expertise in scientific and medical innovation and public health
which will be invaluable to GSK. "
Dr Glimcher is currently Professor of Medicine at Harvard
Medical School and is CEO, President and an Attending Physician at
the Dana-Farber Cancer Institute.
In addition to a number of senior leadership positions held at
both Harvard Medical School and Harvard School of Public Health, Dr
Glimcher has also served as Stephen and Suzanne Weiss Dean and
Professor of Medicine at Weill Cornell Medical College and as an
Attending Physician at the New York Presbyterian Hospital/Weill
Cornell Medical Center.
Dr Glimcher is a member of the Blue Ribbon Panel Advisory Board
of the National Cancer Institute and of the American Asthma
Foundation. She is a Non-Executive Director of the Parker Institute
for Cancer Immunotherapy and of the Waters Corporation, where she
also serves on their Corporate Governance Committee. Dr Glimcher
recently decided to step down from the Board of Bristol-Myers
Squibb Co (BMS) after serving for 20 years on its Board.
Dr Glimcher has recently been awarded the Kober Medal from the
American Association of Physicians for a lifetime of achievements
in the field of internal medicine. She has also received the
L'Oreal Laureate Award for her discoveries in immunology, and the
Marion Fay Spencer award for her scholarship and commitment to the
application of sciences to healthcare. She is also a member of the
Lasker Award Jury, a Fellow of the American Academy of Arts and
Sciences, a Member of the National Academy of Medicine, a Member of
the National Academy of Sciences and a Fellow of the Royal Society
of Biology.
On joining the Board Dr Glimcher will become a member of the
Board's Science and Audit & Risk Committees.
V A Whyte
Company Secretary
21 July 2017
Notes
1. As Non-Executive Director of GSK, Dr Glimcher will receive
standard annual fees of GBP85,000 per annum. She will also receive
a further GBP30,000 in respect of her additional duties as a Board
Scientific and Medical Expert. To enhance the link between
Non-Executive Directors and shareholders, at least 25% of her fees
will be paid in the form of Ordinary Shares and allocated to a
share account, and she will be able to invest part or all of the
balance of her fees into the same share account.
2. The Board has determined that Dr Glimcher will be an
independent Non-Executive Director, in accordance with the UK
Corporate Governance Code. In addition, the Company confirms that
there are no further disclosures to be made in connection with Dr
Glimcher's appointment in accordance with Listing Rule 9.6.13R.
3. "Scientific and Medical Expert" - The Board designates Non
Executive Directors whose expertise or backgrounds as renowned
medical scientists, researchers, or physicians mean that they are
able to bring scientific or industry expertise to the Board's
deliberations.
4. With effect from 1 September 2017, the composition of the Board of GSK will be as follows:
Sir Philip Hampton Non-Executive Chairman
Ms Emma Walmsley Chief Executive Officer
Mr Simon Dingemans Chief Financial Officer
Dr Patrick Vallance President, R&D
Professor Sir Roy Anderson Independent Non-Executive Director
Mr Vindi Banga Senior Independent Non-Executive Director
Dr Vivienne Cox Independent Non-Executive Director
Ms Lynn Elsenhans Independent Non-Executive Director
Dr Jesse Goodman Independent Non-Executive Director
Dr Laurie Glimcher Independent Non-Executive Director
Ms Judy Lewent Independent Non-Executive Director
Mr Urs Rohner Independent Non-Executive Director
GSK - one of the world's leading research-based pharmaceutical
and healthcare companies - is committed to improving the quality of
human life by enabling people to do more, feel better and live
longer. For further information please visit www.gsk.com.
GSK enquiries:
Simon Steel +44 (0) 20 8047 (London)
5502
Eleanor Bunch +44 (0) 20 8047 (London)
5502
US Media enquiries: Sarah Alspach +1 202 715 1048 (Washington,
DC)
Sarah Spencer +1 215 751 3335 (Philadelphia)
Analyst/Investor enquiries: Sarah Elton-Farr +44 (0) 20 8047 (London)
5194
Tom Curry + 1 215 751 5419 (Philadelphia)
Gary Davies +44 (0) 20 8047 (London)
5503
James Dodwell +44 (0) 20 8047 (London)
2406
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including
those made in this announcement, are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors include, but are not limited
to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F
for 2016.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFMGZNLMRGNZG
(END) Dow Jones Newswires
July 21, 2017 06:00 ET (10:00 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024